Neisseria gonorrhoeae infection is an important public health issue, with an annual global
incidence of 87 million. N. gonorrhoeae infection causes significant morbidity and can have …

Infections with Neisseria meningitidis and Neisseria gonorrhoeae have different clinical
manifestations, but the bacteria share up to 80–90% genome sequence identity. The …

Background Gonorrhoea is a major global public health problem that is exacerbated by drug
resistance. Effective vaccine development has been unsuccessful, but surveillance data …

Background A programme of vaccination with the four-component serogroup B
meningococcal (4CMenB) vaccine was introduced in South Australia for infants and children …

Abstract Background Neisseria gonorrhoeae and Neisseria meningitidis are closely-related
bacteria that cause a significant global burden of disease. Control of gonorrhoea is …

Renewed interest in developing vaccines against Neisseria gonorrhoeae has been sparked
by the increasing threat of gonococcal antimicrobial resistance (AMR) and growing optimism …

Gonorrhea is a major global public health problem with emergence of multiple drug-resistant
strains with no effective vaccine. This retrospective cohort study aimed to estimate the …

An experimental gonococcal vaccine consisting of outer membrane vesicles (OMVs) and
microsphere (ms)-encapsulated interleukin-12 (IL-12 ms) induces Th1-driven immunity, with …

The World Health Organization (WHO) has placed N. gonorrhoeae on the global priority list
of antimicrobial resistant pathogens and is urgently seeking the development of new …

Background Neisseria gonorrhoeae cross-protection was suggested in a New Zealand
meningitis B vaccine. We modeled the potential impact of similar vaccines on gonorrhea …